MerLion Pharmaceuticals is a biopharmaceutical company focused on the development of novel antibiotics to treat serious bacterial infections and address antimicrobial resistance.

Based in Berlin, Germany, MerLion manages non-clinical and clinical development as well as active pharmaceutical ingredient and drug product development and manufacturing. Its pipeline includes finafloxacin, a next-generation fluoroquinolone antibiotic with broad-spectrum activity, and friulimicin. The otic suspension of finafloxacin (XtoroTM) has received market approval from the U.S. FDA and Health Canada.